Aspira Women's Health
AWH

$1.49

0.67%

Market Cap: 21.3M

About: Aspira Womens Health Inc is engaged in developing and commercializing diagnostic tests for gynecologic diseases. Its products include OvaSuite which is a portfolio of blood tests that applies proprietary algorithms incorporating patient features; OvaWatch intended for use in assessing the risk of ovarian cancer for women with adnexal masses; and Ova1Plus is a portfolio of blood tests, Ova1Plus is a combination of two FDA-cleared tests for women with pelvic masses who are planned for surgery.

Employees: 64

Healthcare In Vitro & In Vivo Diagnostic Substances

0

Funds holding %

of 6,702 funds

–

Analysts bullish %

–

News positive %

Fund manager confidence

Based on 2024 Q1 SEC filings by fund managers ($100M+ AUM)

150% more repeat investments, than reductions

Existing positions increased: 10 | Existing positions reduced: 4

111% more capital invested

Capital invested by funds: $2.92M [Q4 2023] → $6.15M (+$3.23M) [Q1 2024]

1.31% more ownership

Funds ownership: 0.8% [Q4 2023] → 2.11% (+1.31%) [Q1 2024]

4% less funds holding

Funds holding: 24 [Q4 2023] → 23 (-1) [Q1 2024]

33% less first-time investments, than exits

New positions opened: 2 | Existing positions closed: 3

See Fund Rankings

Research analyst outlook

2 Wall Street Analysts provided 1 year price forecasts over the past 6 months

Low target

$3.30

121%

upside

Avg. target

$3.30

121%

upside

High target

$3.30

121%

upside

2 analyst ratings

0 positive

0%

2 neutral

100%

0 negative

0%

Cantor Fitzgerald Ross Osborn	121%upside $3.3	Neutral Reiterated	10 Apr 2024
Cantor Fitzgerald Ross Osborn	121%upside $3.3	Neutral Maintained	1 Apr 2024

See Analyst Rankings

Financial journalist opinion

Aspira Women's Health Announces Closing of $1.9 Million Private Placement Equity Financing

AUSTIN, Texas, July 09, 2024 (GLOBE NEWSWIRE) -- Aspira Women's Health Inc. (“Aspira” or the “Company”) (Nasdaq: AWH), a bio-analytical based women's health company focused on the development of gynecologic disease diagnostic tools, today announced that it has closed its previously announced private placement for the issuance and sale of shares of the Company's common stock and accompanying warrants to purchase an equal number of shares for gross proceeds of approximately $1.9 million. Aspira has the potential to receive additional gross proceeds of up to $2.8 million, before deducting offering expenses, upon the full cash exercise of warrants issued in the private placement.

Aspira Women's Health Announces Closing of $1.9 Million Private Placement Equity Financing

Aspira Women's Health Announces $1.935 Million Private Placement Equity Financing

AUSTIN, Texas, July 01, 2024 (GLOBE NEWSWIRE) -- Aspira Women's Health Inc. (“Aspira” or the “Company”) (Nasdaq: AWH), a bio-analytical based women's health company focused on the development of gynecologic disease diagnostic tools, today announced it has entered into a securities purchase agreement dated June 30, 2024 with certain existing accredited shareholders and Company insiders to issue and sell an aggregate of 1,264,739 shares of its common stock (“Common Stock”) and warrants to purchase an equal number of shares of Common Stock (“Warrants”) at a combined offering price of $1.53 per share and warrant through a private placement financing (the “Offering”). Aspira anticipates the gross proceeds from the Offering will be approximately $1.935 million, before deducting offering expenses. The warrants will be exercisable for three years after date of issuance and have an exercise price of $2.25 per share. The Offering is expected to close by July 8, 2024 subject to customary closing conditions. Net proceeds from the Offering will support Aspira's ongoing commercial activities as well as general corporate purposes and working capital.

Aspira Women's Health Announces $1.935 Million Private Placement Equity Financing

Aspira Women's Health Provides Commercial, Reimbursement and Cash Guidance Updates

Monthly OvaSuiteSM product volume grew by more than 26% in May compared to January Reimbursement momentum continued with expanded Anthem and Medicaid coverage for OvaSuite Cash used in operations guidance for 2024 expected to be lowered AUSTIN, Texas, June 13, 2024 (GLOBE NEWSWIRE) -- Aspira Women's Health Inc. (“Aspira” or the “Company”) (Nasdaq: AWH), a bio-analytical based women's health company focused on the development of gynecologic disease diagnostic tools, today provided interim commercial and operational updates for the second quarter of 2024. Product volume continued its sustained monthly gains, growing by more than 26% in May 2024 compared to January 2024.

Aspira Women's Health Provides Commercial, Reimbursement and Cash Guidance Updates

Aspira Women's Health to Present at the A.G.P. Healthcare Showcase on May 21

AUSTIN, Texas, May 16, 2024 (GLOBE NEWSWIRE) -- Aspira Women's Health Inc. (“Aspira” or the “Company”) (Nasdaq: AWH), a bio-analytical based women's health company focused on the development of gynecologic disease diagnostic tools, today announced that management will present a corporate overview at the Alliance Global Partner's Healthcare Showcase taking place virtually on Tuesday, May 21, 2024.

Aspira Women's Health to Present at the A.G.P. Healthcare Showcase on May 21

Aspira Women's Health Inc. (AWH) Q1 2024 Earnings Call Transcript

Aspira Women's Health Inc. (NASDAQ:AWH ) Q1 2024 Results Conference Call May 15, 2024 8:30 AM ET Company Participants Nicole Sandford - CEO Sandy Milligan - President Torsten Hombeck - CFO Conference Call Participants Ross Osborn - Cantor Fitzgerald Maggie Boeye - William Blair Do Kim - Water Tower Research Operator Good morning, ladies and gentlemen, and welcome to Aspira Women's Health, Incorporated. First Quarter 2024 Earnings Conference Call.

Aspira Women's Health Inc. (AWH) Q1 2024 Earnings Call Transcript

Zacks Investment Research

Aspira (AWH) Reports Q1 Loss, Tops Revenue Estimates

Aspira (AWH) came out with a quarterly loss of $0.39 per share versus the Zacks Consensus Estimate of a loss of $0.36. This compares to loss of $10.94 per share a year ago.

Aspira (AWH) Reports Q1 Loss, Tops Revenue Estimates

Aspira Women's Health Reports First Quarter 2024 Financial Results

Q1 2024 OvaSuite S M revenue of $2.2 million and volume of 5,829 units

Aspira Women's Health Reports First Quarter 2024 Financial Results

UPDATE -- Aspira Women's Health to Announce First Quarter Earnings Results and Host a Conference Call on Wednesday, May 15

AUSTIN, Texas, May 08, 2024 (GLOBE NEWSWIRE) -- Aspira Women's Health Inc. (“Aspira” or the “Company”) (Nasdaq: AWH), a bio-analytical based women's health company focused on the development of gynecologic disease diagnostic tools, today announced that the Company will report its financial results for the three months ended March 31, 2024, on Wednesday, May 15, 2024. Management will also host a conference call at 8:30 a.m. Eastern Time to discuss financial results and provide a corporate update. Details for the call are as follows:

UPDATE -- Aspira Women's Health to Announce First Quarter Earnings Results and Host a Conference Call on Wednesday, May 15

Aspira Women's Health to Announce First Quarter Earnings Results and Host a Conference Call on Wednesday, May 15

AUSTIN, Texas, May 08, 2024 (GLOBE NEWSWIRE) -- Aspira Women's Health Inc. (“Aspira” or the “Company”) (Nasdaq: AWH), a bio-analytical based women's health company focused on the development of gynecologic disease diagnostic tools, today announced that the Company will report its financial results for the three months ended March 31, 2024, on Wednesday, May 15, 2024. Management will also host a conference call at 8:30 a.m. Eastern Time to discuss financial results and provide a corporate update. Details for the call are as follows:

Aspira Women's Health to Announce First Quarter Earnings Results and Host a Conference Call on Wednesday, May 15

Aspira Women's Health Announces Anthem Blue Cross to Provide Coverage for OvaSuite(SM) in California

Coverage represents approximately 6 million lives, including commercial, Medicare Advantage, and Medicaid Coverage represents approximately 6 million lives, including commercial, Medicare Advantage, and Medicaid

Aspira Women's Health Announces Anthem Blue Cross to Provide Coverage for OvaSuite(SM) in California

See News Rankings